Fischer Medical

Fischer Medical Ventures reported robust financial results for Q2 and H1 FY26, with Q2 revenue reaching INR 86 crores, a significant 118% year-on-year growth. H1 revenue stood at INR 110 crores, increasing by 120% year-on-year. Profitability saw substantial improvement, with Q2 EBITDA at INR 19 crores (a 25-fold increase) and H1 EBITDA at INR 30.5 crores (a 22x increase), translating to margins of 21% and 25% respectively. PAT for Q2 was INR 14 crores (16% margin) and for H1 was INR 19 crores (16% margin), reflecting strong operating leverage and cost optimization.

The company's core expertise is bifurcated into Radiology equipment through Time Medical International Ventures (India) Private Limited, focusing on MRIs and expanding into CT and interop MRIs, and Preventive Health through FlynnCare Health Innovation Private Limited, which provides connected healthcare solutions. Management emphasized making healthcare more accessible through early diagnosis and preventive measures, leveraging AI, cloud-based platforms, and decentralized models of care. The goal is to provide accessible healthcare to everyone, encompassing both diagnostics and preventive solutions.

Fischer Medical's product portfolio includes 1.5 Tesla MRI systems (MICA and QUIN, both helium and helium-free) and open MR systems (PICA) for micro musculoskeletal and spine imaging, offering significant cost and operational advantages over competitors (20-35% lower capex, 10-15% lower opex). The company is also developing AI-enabled interop MRIs for neurosurgery and integrating AI-driven diagnostics, teleradiology, and indigenous manufacturing into a seamless ecosystem. This fusion aims to set new benchmarks for cost-effectiveness and high performance in medical imaging.

The company is actively expanding its market presence, with H1 FY26 revenues showing a significant shift towards international markets, where 30% of revenue originated, up from 5-10% in the previous year, while India contributed 70%. Management targets a 15-20% market share in the domestic and Asian MRI markets. The Indian MRI market is projected to grow from 500 units per year at a 15% CAGR to over 1000 units per year in the next 3-4 years, driven by government mandates for tertiary hospitals.

Fischer Medical currently has an MRI manufacturing capacity of 80 machines per year on a single shift, which can be scaled up to 150-160 machines per year with two shifts. The company is awaiting final CDSCO approval for its Nanomedic skin technology, expected by the end of November 2025, with commercial deployment anticipated in Q3 or Q4 FY26. Initial rollout of preventive health screening in schools is underway, with a refined version 1 of the health kiosk deployment expected in Q3 and Q4 FY26.

The Indian healthcare landscape is undergoing rapid transformation, supported by government programs like Ayushman Bharat, National Health Mission, and Digital Health Mission, which are expanding access to quality and affordable healthcare. The "Make in India" and PLI schemes for medical devices are encouraging domestic innovation, positioning Fischer Medical to benefit from the projected 15-20% growth in the Medtech sector. The company sees good traction from government policies, though specific projections for government tenders are not provided due to their nature.